Lithuania

Lithuania has emerged as one of Europe’s fastest-growing life sciences ecosystems, boasting an average annual growth rate of over 20% and a strategic goal to contribute 5% of national GDP by 2030.

The nation is globally recognized for its world-class biotechnology sector, particularly as a pioneer in gene editing and CRISPR-Cas9 technologies led by the renowned Vilnius University Life Sciences Center.

Its robust pharmaceutical landscape is anchored by industry leaders who specialize in biomanufacturing, enzyme production and high-purity reagents.

In the medical device sector, Lithuania excels in integrating laser technologies, precision engineering and digital health solutions, making it a premier hub for medtech innovation.

The country’s healthcare innovation is further propelled by a burgeoning startup scene focused on personalized medicine, AI-driven diagnostics and cell and gene therapies.

Academic excellence is the ecosystem's backbone, with the Lithuanian University of Health Sciences and Vilnius University fostering high-impact academic research and a steady pipeline of STEM talent.

Lithuania also offers a globally integrated environment for clinical trials, supported by transparent regulatory frameworks and open-access national health data.

This collaborative "triple helix" of government, academia and industry creates a fertile ground for R&D investment and cross-border partnerships. From synthetic biology to advanced biologics, Lithuania is not just participating in the future of medicine; it is actively engineering it.